ConductScience.org, home

Paper32100240

The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients-Part I: Early-Stage Disease.

Sammons S and 2 others. Drugs Aging, 2020. Cited by 4 papers, by iCite.

Cite this record

ConductScience Library. The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients-Part I: Early-Stage Disease. Papers, record 32100240. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32100240

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients-Part I: Early-Stage Disease.
PubMed
Journal
Drugs Aging
PubMed
Year
2020
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
4
iCite
Relative citation ratio, by iCite
0.24
iCite
Revised in PubMed
2026-10-10
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Sammons SSarahhttps://orcid.org/0000-0003-2589-9422
2Sedrak MSMina Shttps://orcid.org/0000-0002-8379-391X
3Kimmick GGGretchen Ghttps://orcid.org/0000-0001-7096-9624

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
Aromatase InhibitorsMajor topic
Breast NeoplasmsMajor topic
Receptors, Cell SurfaceMajor topic
TamoxifenMajor topic
Aged
Chemotherapy, Adjuvant
Combined Modality Therapy
Early Detection of Cancer
Female
Geriatric Assessment
Humans
Neoplasm Staging
Practice Guidelines as Topic
Erb-b2 Receptor Tyrosine Kinases

Source PubMed

Download CSV of topics

References167

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
11746054Response of primary breast cancer to tamoxifen alone in elderly women.Tumori1991https://conductscience.org/library/papers/1746054PubMed
221371853A population-based validation of the prognostic model PREDICT for early breast cancer.Eur J Surg Oncol2011https://conductscience.org/library/papers/21371853PubMed
32895214Prospective randomised trial of tamoxifen versus surgery in elderly patients with breast cancer.Lancet1988https://conductscience.org/library/papers/2895214PubMed
414588130Aging may be associated with concentrations of tamoxifen and its metabolites in breast cancer patients.J Womens Health (Larchmt)2003https://conductscience.org/library/papers/14588130PubMed
526884586Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression.J Clin Oncol2016https://conductscience.org/library/papers/26884586PubMed
629932846Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology Summary.J Oncol Pract2018https://conductscience.org/library/papers/29932846PubMed
724197662Impact of SERM adherence on treatment effect: International Breast Cancer Study Group Trials 13-93 and 14-93.Breast Cancer Res Treat2013https://conductscience.org/library/papers/24197662PubMed
827992272Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527.J Clin Oncol2017https://conductscience.org/library/papers/27992272PubMed
912039943Association of tamoxifen and uterine sarcoma.J Clin Oncol2002https://conductscience.org/library/papers/12039943PubMed
1014513434Pharmacokinetics of third-generation aromatase inhibitors.Semin Oncol2003https://conductscience.org/library/papers/14513434PubMed
1115591335A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.N Engl J Med2004https://conductscience.org/library/papers/15591335PubMed
1222152852The 2011 EBCTCG polychemotherapy overview.Lancet2012https://conductscience.org/library/papers/22152852PubMed
1312538506National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ.Clin Cancer Res2003https://conductscience.org/library/papers/12538506PubMed
1426277113A pharmacist-led medication assessment used to determine a more precise estimation of the prevalence of complementary and alternative medication (CAM) use among ambulatory senior adults with cancer.J Geriatr Oncol2015https://conductscience.org/library/papers/26277113PubMed
1523949153The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study.Br J Cancer2013https://conductscience.org/library/papers/23949153PubMed
1617470740Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy.J Natl Cancer Inst2007https://conductscience.org/library/papers/17470740PubMed
1722318280Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer.JAMA2012https://conductscience.org/library/papers/22318280PubMed
1830787125NCCN Guidelines Insights: Breast Cancer, Version 3.2018.J Natl Compr Canc Netw2019https://conductscience.org/library/papers/30787125PubMed
1929128896Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer.Breast Cancer Res Treat2018https://conductscience.org/library/papers/29128896PubMed
2010615079Underrepresentation of patients 65 years of age or older in cancer-treatment trials.N Engl J Med1999https://conductscience.org/library/papers/10615079PubMed

See all 167 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.

PMIDTitleJournalYearIn PapersSource
40004963A Systematic Review of Vitamin D Supplementation in Oncology: Chance of Science or Effectiveness?Nutrients2025https://conductscience.org/library/papers/40004963PubMed
34893669Epigenome association study for DNA methylation biomarkers in buccal and monocyte cells for female rheumatoid arthritis.Sci Rep2021https://conductscience.org/library/papers/34893669PubMed

Download CSV of cited by

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CDK41019PubTator's text mininghttps://conductscience.org/library/genes/1019NCBI Gene
CDK61021PubTator's text mininghttps://conductscience.org/library/genes/1021NCBI Gene
ERBB22064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
NR4A13164PubTator's text mininghttps://conductscience.org/library/genes/3164NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/32100240

GET https://conductscience.org/api/papers/v1/32100240/references?page=2